


FIGURE 1: Dissolution profile of acamprosate calcium enteric-coated sprinkles (#25/30)

FIGURE 2: Dissolution profile of open petri plate study for sprinkles with 5% ethyl cellulose + 40% enteric coating




FIGURE 3: Dissolution profile of open petri plate study for sprinkles with 10% ethyl cellulose + 40% enteric coating




FIGURE 4: Dissolution profile of open petri plate study for sprinkles with 10% ethyl cellulose + 30% enteric coating




FIGURE 5: Dissolution profile of Acamprosate Calcium Sprinkles (5% ethyl cellulose + 40% eudragit coating)




FIGURE 6: Dissolution profile of Acamprosate Calcium Sprinkles (5% ethyl cellulose + 40% eudragit coating)




FIGURE 7: Day 1 PK during the first 12 hour period




FIGURE 8: Day 1 PK for the 666 mg BID study




FIGURE 9: PK- 1332 mg (666 mg BID) Day 1--Campral vs. SF679 vs. SF775 (left) compared to Campral vs. SF999 (right)





FIGURE 10: PK- 1332 mg (666 mg BID) Day 1 vs. Day 4--Campral vs. SF679 vs. SF775